Published: 3. June, 2024
Cessatech announces the final simulated efficacy data in children with CT001 from the abstract…
Cessatech announces the final simulated efficacy data in children with CT001 from the abstract that will be presented at the Population Approach Group Europe (PAGE) conference in Rome Italy, during 26–28 June 2024.
- The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively.
- Estimates for the opioid sparing effect of ketamine showed a need for more than double the sufentanil exposure to get the same overall effect seen with the treatment of CT001.
- The data supports the earlier reported data from the Dental Study 0205 showing the effectiveness of treatment with CT001. The full simulated data set will be presented at the PAGE conference in Rome 26-28 June.
Press release
240306 – CT001 simulated pain in children
Jes Trygved, CEO, Cessatech
“We are very pleased with the final simulated results and the opportunity to present them at the prestigious PAGE conference. The data strongly support our hypothesis that CT001 is very effective in children relative to its active comparators and will be instrumental in our further development. A great effort by the team and CT001 is now one step closer to finalize the clinical program and becoming available to hospitals and the children that really need approved, easy to administer pain relief.”
